Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)

NCT04230109 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT04230109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
July 14, 2020
Completion date
October 31, 2029
Enrollment
239 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

er-negative breast cancer, her2-negative breast cancer, invasive breast cancer, pr-negative breast cancer, triple negative breast cancer